Evolution of the Average Target: Structure Therapeutics Inc.

Evolution of the Average Target - Structure Therapeutics Inc.

Evolution of the Target Price: Structure Therapeutics Inc.

Evolution of the Target Price - Structure Therapeutics Inc.

Changes in Analyst Recommendations: Structure Therapeutics Inc.

798.Ql6H4cJZiuF0heoB9hdpayYQLBBxAezrGLLIhuxEkiE.dwfOg5Uf7ZRN84lntG0NDn9PSXsJbKC4b8T66aZyyFMzF9--nSP-qi3DmQ~6c207230f10835e62744e4a3606892e3
11-13 Morgan Stanley Adjusts Price Target on Structure Therapeutics to $117 From $126, Keeps Outperform Rating MT
04-27 Canaccord Genuity Initiates Coverage on Structure Therapeutics With Buy Rating, $101 Price Target MT
07/08/25 Assembly Biosciences Q2 revenue rises from Gilead collaboration RE
02/05/25 Citigroup Initiates Coverage on Structure Therapeutics With Buy Rating, $60 Price Target MT
28/02/25 William Blair Initiates Structure Therapeutics at Outperform MT
04/12/24 HC Wainwright Initiates Structure Therapeutics at Buy MT
23/09/24 Structure Therapeutics Shares Rise After Morgan Stanley Begins Coverage at Overweight MT
23/09/24 Morgan Stanley Initiates Structure Therapeutics at Overweight MT
07/06/24 BMO Capital Adjusts Price Target on Structure Therapeutics to $100 From $83, Maintains Outperform Rating MT
21/05/24 JPMorgan Starts Structure Therapeutics With Overweight Rating MT
09/04/24 Cantor Fitzgerald Initiates Structure Therapeutics at Overweight Rating With $65 Price Target MT
15/11/23 JMP Securities Adjusts Structure Therapeutics' Price Target to $91 From $90, Keeps Market Outperform Rating MT
27/10/23 Piper Sandler Raises Price Target on Structure Therapeutics to $93 From $58, Maintains Overweight Rating MT
19/10/23 JMP Securities Starts Coverage on Structure Therapeutics with Market Outperform Rating, $90 Price Target MT
03/10/23 BMO Capital Adjusts Structure Therapeutics Price Target to $83 From $40, Maintains Outperform Rating MT
27/07/23 Piper Sandler Initiates Structure Therapeutics With Overweight Rating, $58 Price Target MT
28/02/23 SVB Securities Initiates Structure Therapeutics at Outperform Rating With $33 Price Target MT
28/02/23 BMO Capital Initiates Structure Therapeutics at Outperform With $40 Price Target MT
28/02/23 Jefferies Initiates Structure Therapeutics at Buy With $34 Price Target MT
28/02/23 Guggenheim Starts Structure Therapeutics at Buy With $50 Price Target MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+464.66%
+40.11%
+15.84%
+7.38%
+14.09%
+17.81%
+29.86%
+64.61%
+18.88%
+58.03%
Average +73.13%
Weighted average by Cap. +28.72%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
18.57USD
Average target price
104.86USD
Spread / Average Target
+464.66%
High Price Target
145.00USD
Spread / Highest target
+680.83%
Low Price Target
70.00USD
Spread / Lowest Target
+276.95%

Analyst Consensus Detail

Analyst consensus - Structure Therapeutics Inc.

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Structure Therapeutics Inc.
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Structure Therapeutics Inc.
  1. Stock Market
  2. Stocks
  3. GPCR Stock
  4. Consensus Structure Therapeutics Inc.